Investors sold shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) on strength during trading on Tuesday. $76.55 million flowed into the stock on the tick-up and $139.04 million flowed out of the stock on the tick-down, for a money net flow of $62.49 million out of the stock. Of all stocks tracked, Alexion Pharmaceuticals had the 13th highest net out-flow for the day. Alexion Pharmaceuticals traded up $1.77 for the day and closed at $124.48

ALXN has been the topic of a number of research analyst reports. Royal Bank of Canada upped their price target on shares of Alexion Pharmaceuticals to $166.00 in a research report on Tuesday, October 24th. Zacks Investment Research raised shares of Alexion Pharmaceuticals from a “hold” rating to a “buy” rating and set a $144.00 price target on the stock in a research report on Tuesday, October 31st. Stifel Nicolaus cut their price target on shares of Alexion Pharmaceuticals from $165.00 to $159.00 and set a “buy” rating on the stock in a research report on Tuesday, October 24th. Leerink Swann reaffirmed a “buy” rating and set a $182.00 price target on shares of Alexion Pharmaceuticals in a research report on Monday, September 25th. Finally, Credit Suisse Group reaffirmed a “buy” rating and set a $166.00 price target on shares of Alexion Pharmaceuticals in a research report on Tuesday, December 12th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and nineteen have given a buy rating to the company. Alexion Pharmaceuticals presently has an average rating of “Buy” and an average target price of $154.00.

The firm has a market capitalization of $27,810.00, a PE ratio of 55.57, a PEG ratio of 1.03 and a beta of 1.17. The company has a quick ratio of 2.51, a current ratio of 2.96 and a debt-to-equity ratio of 0.35.

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.44 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.32 by $0.12. The company had revenue of $859.00 million for the quarter, compared to analysts’ expectations of $864.34 million. Alexion Pharmaceuticals had a net margin of 14.57% and a return on equity of 12.55%. The business’s revenue was up 7.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.23 EPS. research analysts expect that Alexion Pharmaceuticals, Inc. will post 4.82 EPS for the current year.

In other news, CEO Ludwig Hantson sold 2,553 shares of the stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $121.63, for a total transaction of $310,521.39. Following the transaction, the chief executive officer now owns 36,172 shares of the company’s stock, valued at approximately $4,399,600.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 4.35% of the stock is owned by corporate insiders.

Hedge funds have recently added to or reduced their stakes in the company. Jennison Associates LLC raised its holdings in shares of Alexion Pharmaceuticals by 720.0% in the 3rd quarter. Jennison Associates LLC now owns 5,332,636 shares of the biopharmaceutical company’s stock worth $748,116,000 after acquiring an additional 4,682,336 shares during the last quarter. Assenagon Asset Management S.A. raised its holdings in shares of Alexion Pharmaceuticals by 4,509.0% in the 3rd quarter. Assenagon Asset Management S.A. now owns 884,150 shares of the biopharmaceutical company’s stock worth $124,037,000 after acquiring an additional 864,967 shares during the last quarter. USA Financial Portformulas Corp acquired a new stake in shares of Alexion Pharmaceuticals in the 3rd quarter worth about $3,632,000. IFC Holdings Incorporated FL acquired a new stake in shares of Alexion Pharmaceuticals in the 3rd quarter worth about $861,000. Finally, Chicago Equity Partners LLC acquired a new stake in shares of Alexion Pharmaceuticals in the 3rd quarter worth about $320,000. 94.27% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This news story was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be accessed at https://www.thecerbatgem.com/2018/01/16/traders-sell-shares-of-alexion-pharmaceuticals-alxn-on-strength-alxn.html.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.